Apogee Therapeutics (APGE) AI Stock Analysis

• Market Cap: $2.42B
• Dividend Yield: N/A
• Average Volume (3M): 1.14M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.64
• Revenue Growth: N/A
• EPS Growth: -94.92%
• Country: US
• Employees: 196
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.95
• Shares Outstanding: 46,047,417
• 10 Day Avg. Volume: 1,004,534
• 30 Day Avg. Volume: 1,140,948
• PEG Ratio: 1.55
• Price to Book (P/B): 3.22
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.48
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -58.78K
• Enterprise Value/Ebitda: -2.76
• 1Y Price Target: $96.75
• Price Target Upside: 132.35% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 49 Neutral
• Price Target: ―

The overall score reflects the company's early-stage biotech position, with significant financial risks due to no revenue and high cash burn. Positive clinical trial results and a strong cash position are key strengths, but valuation concerns and technical analysis suggest caution.

Positive Factors

Analyst Recommendation

Analyst reiterates a Buy rating for Apogee Therapeutics with a price objective of $78, indicating confidence in the company's future prospects.

Efficacy and Safety

APG777 demonstrated best-in-class efficacy and clean safety in atopic dermatitis.

Market Opportunity

Atopic dermatitis is expected to emerge as the largest market in dermatology, providing ample growth opportunity for APG777.

Negative Factors

Adverse Events

Conjunctivitis rates are modestly higher for APG777, an adverse event common to all drugs in this class.

Payer Coverage

Securing payer coverage remains a key challenge for APG777 as a later-entrant product in the market.

Apogee Therapeutics Business Overview & Revenue Model

Company Description

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

How the Company Makes Money

Apogee Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company generates revenue through partnerships and collaborations with other pharmaceutical companies, licensing agreements, and potential milestone payments related to the successful development and commercialization of its therapies. Additionally, Apogee may earn revenue from selling its developed therapeutics once they receive regulatory approval and are brought to market.

Apogee Therapeutics Financial Statement Overview

Summary

Apogee Therapeutics is typical of early-stage biotech firms with no revenue and increasing operational expenses. The company relies heavily on equity financing, reflected in low debt and strong cash positions. However, the absence of revenue and high cash burn present significant risks.

Income Statement

Apogee Therapeutics has reported zero revenue over the past three years, which is typical for early-stage biotechnology firms focusing on research and development. The company’s EBIT and EBITDA have significantly worsened, reflecting increased operational expenses without revenue offset. The absence of revenue growth and negative net income margins highlight substantial profitability challenges.

Balance Sheet

The balance sheet shows a strong equity position with a substantial increase in stockholders’ equity, driven by financing activities likely tied to capital raises. The debt-to-equity ratio remains low, indicating minimal leverage. However, total assets are primarily composed of cash and equivalents, which could indicate a lack of diversification in asset allocation.

Cash Flow

The company’s cash flow statement shows significant reliance on financing activities to fund operations, typical for biotech companies in the development phase. Operating cash flow is negative, consistent with its stage, but free cash flow has deteriorated, indicating increasing cash burn rates. This trend could pose liquidity risks if external funding becomes challenging.

Breakdown	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00
EBITDA	-216.87M	-83.98M	0.00
Net Income	0.00	-83.98M	-39.78M
Balance Sheet
Total Assets	753.95M	401.40M	152.06M
Cash, Cash Equivalents and Short-Term Investments	520.65M	395.46M	151.89M
Total Debt	11.83M	2.03M	0.00
Total Liabilities	37.16M	21.49M	9.98M
Stockholders Equity	716.79M	379.91M	-39.78M
Cash Flow
Free Cash Flow	-172.33M	-74.93M	-16.43M
Operating Cash Flow	-171.17M	-74.76M	-16.43M
Investing Cash Flow	-300.46M	-273.91M	0.00
Financing Cash Flow	495.11M	315.39M	183.62K

Apogee Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 41.64
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APGE, the sentiment is Positive. The current price of 41.64 is above the 20-day moving average (MA) of 40.48, above the 50-day MA of 40.26, and below the 200-day MA of 42.26, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 55.07 is Neutral, neither overbought nor oversold. The STOCH value of 82.26 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for APGE.

Apogee Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LGND	58 Neutral	$2.63B	48.01	-16.56%	―	53.40%	-230.86%
TARS	56 Neutral	$1.77B	―	-33.98%	―	449.03%	42.86%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
APGE	49 Neutral	$2.42B	―	-27.85%	―	―	-94.92%
BLTE	43 Neutral	$2.03B	―	-33.43%	―	―	4.80%
AAPG	43 Neutral	$3.44B	―	-253.16%	―	331.22%	59.40%
BHVN	40 Underperform	$1.40B	―	-316.82%	―	―	-65.63%

Apogee Therapeutics Corporate Events

Apogee Therapeutics Reports Positive Phase 1 Results

On March 3, 2025, Apogee Therapeutics announced positive interim Phase 1 results from its first-in-human trial of APG990, which exceeded trial objectives and demonstrated potential for extended dosing intervals. The company also reported significant progress in its pipeline, including the accelerated execution of the Phase 2 APEX clinical trial for APG777 and plans for further trials in asthma and eosinophilic esophagitis. Apogee’s strong financial position, with $731.1 million in cash and marketable securities, supports its operations into 2028, despite increased R&D and G&A expenses in 2024.